KRAS and non-small cell lung carcinoma: This intricate molecular crosstalk between KRAS-driven signaling and TTP-mediated post-transcriptional regulation not only provides novel insights into the mechanisms of immune evasion in NSCLC but also highlights potential therapeutic targets for modulating PD-L1 expression in KRAS-mutant tumors.